© Copyright - Newspaper WordPress Theme by TagDiv
Enalapril Maleate
Also known as / Synonyms: Enalapril, Enalaprilat precursor
ACE inhibitor lowering elevated blood pressure and improving survival in heart failure and LV dysfunction.
Clinical Snapshot & Specifications
Approved Indications & Medical Uses
- Treatment of essential and renovascular hypertension.
- Symptomatic heart failure as guideline-directed therapy (with diuretics and digitalis).
- Asymptomatic left ventricular dysfunction (LVEF <= 35%) to reduce hospitalization and mortality.
Contraindications (Do Not Use If…)
- History of angioedema related to previous ACE inhibitor therapy or hereditary/idiopathic angioedema.
- Concomitant use with aliskiren in patients with diabetes or renal impairment.
- Concomitant use with neprilysin inhibitors (sacubitril/valsartan) within 36 hours (angioedema risk).
- Second and third trimesters of pregnancy (fetal toxicity/death).
- Bilateral renal artery stenosis.
Important Clinical Precautions & Warnings
- Fetal toxicity: Discontinue immediately when pregnancy is detected; causes oligohydramnios, skull hypoplasia, and fetal death.
- Angioedema: Can affect face, lips, tongue, glottis, and bowel; airway compromise requires emergency epinephrine.
- Hypotension: First-dose hypotension can occur in volume- or salt-depleted patients.
- Hyperkalemia: Monitor serum potassium, especially with potassium supplements or renal impairment.
- Renal function deterioration: Monitor serum creatinine during initiation.
Special Populations (Paediatric & Geriatric Care)
Pediatric: Approved for hypertension in children >= 1 month; not recommended in GFR < 30 mL/min. Elderly: Start at lower dose (2.5 mg) due to decreased renal clearance.
Side Effects & Adverse Reactions
Common Side Effects (Usually Mild)
Persistent dry hacking cough, dizziness, headache, fatigue, hypotension, diarrhea, and nausea.
Serious Side Effects — Seek Urgent Medical Care
Laryngeal angioedema, acute renal failure, life-threatening hyperkalemia, neutropenia/agranulocytosis, and hepatic failure/cholestatic jaundice.
Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.
Drug, Food & Substance Interactions
- Potassium-sparing diuretics (spironolactone, eplerenone) and potassium supplements: high risk of severe hyperkalemia.
- NSAIDs (ibuprofen, naproxen): attenuate antihypertensive effect and worsen acute kidney injury.
- Lithium: decreased renal clearance of lithium leading to lithium toxicity.
- Sacubitril/valsartan: strictly contraindicated within 36 hours due to angioedema risk.
Pregnancy & Lactation Clinical Safety
Pregnancy Safety:
ContraindicatedContraindicated in pregnancy (especially 2nd and 3rd trimesters). Can cause fetal renal failure, oligohydramnios, skeletal deformities, and neonatal death.
Lactation & Breastfeeding:
Use with caution — see notesEnalapril and enalaprilat are excreted in breast milk in small amounts; use with caution in full-term infants, avoid in preterm infants.
Storage, Administration & Overdose Protocol
🌡️ Recommended Storage:
Store below 30°C in a dry place. Protect from moisture and excessive heat.
⏱️ Missed Dose Protocol:
Take once or twice daily with or without food. If missed, take upon remembering unless close to next scheduled dose.
Overdose causes profound hypotension, stupor, and renal failure. Treat with IV normal saline infusion for volume expansion and supportive care.
Clinical Sources & Regulatory References
Statutory drug monograph citations and regulatory databases consulted for clinical synthesis.
Every clinical monograph on 4mg.in is continuously cross-referenced against official pharmacopoeias, national formulary compendia, and statutory regulatory filings to guarantee therapeutic precision:
Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare. Evaluated for approved indications, Schedule H/H1 status, and National List of Essential Medicines (NLEM).
CDSCO Official Portal →U.S. Food and Drug Administration Approved Prescribing Information, Package Inserts, and Pharmacovigilance Black Box Warnings repository via NLM DailyMed.
Search FDA Labels on DailyMed →WHO Model List of Essential Medicines (23rd List) and WHO Collaborating Centre for Drug Statistics Methodology (Anatomical Therapeutic Chemical - ATC / DDD Index).
WHO Essential Medicines Registry →National Center for Biotechnology Information (NCBI). Peer-reviewed clinical trials, bioavailability investigations, and Cochrane systematic reviews.
Query PubMed Studies for Enalapril Maleate →
4mg Clinical Pharmacology Team. Enalapril Maleate Monograph: Uses, Dosage, Contraindications & Interactions. Medically reviewed by licensed clinical editors. 4mg.in, 2026. Available at: https://4mg.in/medicines/enalapril/
